Omnicell, Inc. (OMCL) Earnings Call Transcripts

Omnicell, Inc.'s Latest Earnings Call - June 9, 2026

In the Q1 2026 earnings call for Omnicell, Inc. (OMCL:US), management reported a strong revenue performance, exceeding expectations and signaling a return to growth after a challenging period. Revenue guidance for the fiscal year remains unchanged, with management highlighting a disciplined approach to spending and improved gross margins. The company is optimistic about its new product cycle and the transition to a more software-centric business model, which could enhance future profitability.

Reported metrics

Guidance from management

Management maintained revenue guidance for FY2026 at $600M, indicating confidence in their growth trajectory despite market uncertainties. They also signaled that profitability metrics are expected to improve throughout the year.

What management said

Sure. Well, the pandemic was a big acceleration of our business and really brought in the product cycle so we saw decreased growth, probably for the first time in a long time in '23 and '24. Now we've returned to growth in '25. We've launched a new product. We're standing on the precipice of our next cycle of brand new, exciting products, both front end, back end. And we've also entered a specialty pharmacy in a big ...

I mean, great question. In the on-prem equipment basis, you can deliver about 2 software upgrades a year, maybe a major and a minor -- as we move to the cloud, we have upgrades every 30 days. And so our ability to accelerate innovation, accelerate results and provide more services for our customers, what we're actually doing the hands-on work maybe of some of the optimization and other things is more enabled by that.

What analysts pressed on

Analysts expressed concerns regarding the transition between product cycles and the potential impact on revenue consistency. There were also questions about the sustainability of gross margins given market pressures and the competitive landscape.

Main topics on the call

• Return to Revenue Growth — Omnicell has returned to growth after a decline in 2023 and 2024, with management stating, "We've launched a new product. We're standing on the precipice of our next cycle of brand new, exciting products." This indicates...
• Transition to Software-Centric Model — Management emphasized the shift from hardware to software services, stating, "It's becoming more software services centric... You need all the intelligence that helps you get drugs to the right place." This transition is...
• Product Cycle Management — Omnicell is strategically managing the transition from its XT series to the new Titan X platform, ensuring a smooth rollout. Randall Lipps noted, "We're still going to be able to sell our old Series XT as well as our Tit...
• Cost Management and Margins — The company reported favorable gross margins in Q1, higher than the normal range, and management indicated that they expect improvements in 2026. They stated, "We saw favorable gross margins in the first quarter, a littl...

Read the full Omnicell, Inc. transcript (June 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 43 Omnicell, Inc. earnings call transcripts on record, spanning January 16, 2020 to July 30, 2026. Based on this history, Omnicell, Inc. reports quarterly. The most recent call on file is dated July 30, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

OMCL

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

43

First call

January 16, 2020

Most recent

July 30, 2026

Reporting cadence

quarterly